Response to Interleukin (IL)-17 Inhibition in an Adolescent With Severe Manifestations of IL-36 Receptor Antagonist Deficiency (DITRA)

JAMA Dermatol. 2017 Jan 1;153(1):106-108. doi: 10.1001/jamadermatol.2016.3490.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal, Humanized
  • Biopsy
  • Dose-Response Relationship, Drug
  • Drug Therapy, Combination
  • Follow-Up Studies
  • Humans
  • Injections, Subcutaneous
  • Interleukin 1 Receptor Antagonist Protein / deficiency*
  • Interleukin-17 / antagonists & inhibitors*
  • Interleukins / genetics
  • Interleukins / metabolism
  • Male
  • Mutation
  • Psoriasis / drug therapy*
  • Psoriasis / genetics
  • Psoriasis / metabolism
  • Skin / pathology

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • IL17A protein, human
  • IL36RN protein, human
  • Interleukin 1 Receptor Antagonist Protein
  • Interleukin-17
  • Interleukins
  • secukinumab